[ad_1]
The research paper published by Xiaohui Zhou titled "A Cardiac Support Device (ASD)) provides bone marrow stem cells repeatedly to the epicardium has promising healing effects on advanced heart failure. Zhou's work is directly related to heart failure, a common and multiple problem in the cardiovascular system (CVS), a disease that causes various complex symptoms and ultimate death. "
According to the Center for Disease Control and Prevention (CDC), heart failure occurs when the heart can not pump enough blood and oxygen to support other organs in the body. Heart failure is a serious illness, but that does not mean that the heart has stopped beating. It is a condition characterized by structural or functional cardiac abnormalities. This condition eventually leads to insufficient filling of the ventricles, resulting in the creation of an imbalance in the energy demand between the heart and the body, as well as many other complications.
Zhou and his colleagues observed that clinical research has progressed in the diagnosis, prevention, and management of heart failure, but remains elusive, with heart failure being the leading cause of death in developed countries . The team of researchers also cited data indicating that 20 million deaths were due to heart failure and that the incidence would increase due to the aging of the population. Zhou's inspiration on this subject stems from a thorough study of this disease.
Zhou has badyzed various interventional therapies such as percutaneous coronary intervention (PCI), ventricular reconstruction therapy such as the cardiac badist device (CSD), which have been developed for the management of the disease. ;heart failure. However, no attention has been paid to the role of the epicardium in the management of heart failure. Thus, Zhou invented a new multifunctional platform equipped with both Hydraulic Ventricular Attachment Support System (ASD) for diagnosis and active management – to manage heart failure. According to Zhou's work, the ASD device is made of highly biocompatible material (silicon) and consists of hollow tubes interconnecting with each other (a detailed form can be found in Zhou's research papers). The ASD system can directly shape the heart and help the heart to pump blood by force from the liquid in the ASD system tubes, which transfers energy to the core from the connected power system. on the outside of the thoracic cavity.
Meanwhile, some openings on the inner surface of the tubes can generate material communications or signals between the core and the TSA. The ASD can also be connected to one or more systems outside the body. Thus, by TSA, drug / biological stem cells, in particular, could flow directly outside the tubules of TSA on the epicardium to produce a direct biological disease on cardiomyocytes or other cardiac tissues with a small dose of medicine in the bloodstream. In addition, many signals, such as electromagnetic signals, could also be transferred if relative sensors could be placed on the surface of the internal openings of the ASD device.
Zhou also emphasized ASD as a surgical option without heart transplant for the management of heart failure. The TSA could have been affected by a single adjustable and measurable ventricular retainer (VRD) to shape the heart. However, according to Zhou and his colleagues, stem cell transplantation of bone marrow and ASD is worthy of achieving better therapeutic outcomes. In their work, as part of the comprehensive ASD treatment platform, they also demonstrated that the unique features of ASDs have promising therapeutic results for relieving heart failure symptoms, which is even more beneficial. than the only restraint therapy.
The results of the team's experiment showed that heart failure was induced by ligation of the left anterior descending coronary artery (LAD) in all groups, except for the control group. It was found that post-infarction electrocardiography (ECG) and cerebral natriuretic peptide (BNP) exhibited abnormal cardiac function. This was revealed in all model groups and the HF + ASD-BMSCs group showed a remarkable improvement over other heart failure groups, the HF + ASD groups at day 30.
The thorough investigation has shown that ASDs have remarkable benefits: the administration of drugs by TSA could produce more durable, accurate and effective results in the treatment of heart failure than flat ones. unique therapeutic forms. In addition, Zhou and colleagues are attempting to monitor the dynamic and biochemical physiology of cardiac function in real time by attaching the microsensor to the surface of the ASD. Ultimately, Zhou's team is committed to building a unified multifunctional unified processing platform. The ASD device proved to be feasible for the operation, and it improved cardiac performance with improved myocardial structure and function, it was observed that the severity of heart failure could be significantly reduced without the discovery of dysfunction of other organs such as renal up to now. It is highly recommended to research and evaluate Zhou's work to understand the importance of his work.
In conclusion, Zhou and his collaborators proved for the first time that a combination of VRD and stem cell planting gave great prospects for the treatment of heart failure. According to Zhou, future efforts should focus on equipping the ASDs with different micro-biosensors to receive more signals from the heart to enhance their potential, both for effective diagnosis and effective treatment of heart failure.
Zhou's work has the potential to save lives that are plagued by this disease. Early diagnosis and treatment with ASD may also improve quality and life expectancy. Zhou's contribution to the field of advanced heart failure would therefore be recognized by physicians.
About: Principal Investigator
Zhou Xiaohui, MD and postdoctoral pharmacy. His research focuses on clinical medicine education and the pharmacology of new drug development. Since 1994, he is involved in clinical work in cardiovascular thoracic surgery, he has until now supervised various national projects in natural sciences. The research of his projects rests on solid theoretical and practical foundations.
References:
The list of published articles relating to the ASD device:
1. Mikrani R, Liang C, Naveed M, Kamboh AA, Abbas M, Chaurasiya B, Xue L and Xiaohui Z. A cardiac troponin I was studied in a canine model of minimally invasive myocardial infarction. Journal of Applied Biomedicine. 2018.
2. Yue S, Naveed M, Gang W, Chen D, Wang Z, Yu F, and Zhou X. A cardiac support device (ASD) delivers stem cells from the bone marrow repeatedly to the epicardium, which which has promising healing effects in advanced heart failure. Biomed Microdevices. 2018; 20: 40.
3. Yasmeen S, Liao X, Khan Fu, Ihsan AU, Li X, Li C, Chen D, Yu F, Wang Z, Sembatya KR, Mikrani R and Zhou X. A new approach to conceive the treatment of ventricular fibrillation by epicardium lidocaine administration with the help of an active hydraulic ventricular fixation support system: experimental study in the rat. Biomed Mater Res B Appl Biomater. 2018.
4. Naveed M, Mohammad IS, Xue L, Khan S, Gang W, Cao Y, Cheng Yi, Cui X, C DingDing, Feng Y, Zhijie W and Xiaohui Z. The Promising Future of Ventricular Retention Therapy for the management of end heart failure in two stages. Biomed Pharmacother. 2018; 99: 25-32.
5. Naveed M, Han L., GJ Khan, Yasmeen S., Mikrani R., Abbas M., Cunyu L and Xiaohui Z. Cardio-Support Devices (VRD & DCC Devices) and Advanced Heart Failure Patches: A Report , summary of the state of the art and future directions. Biomed Pharmacother. 2018; 102: 41-54.
6. Nawaz W, Khan FU, Khan MZ, Gang W, Yang M, Liao X, Zhang L, Ihsan UA, Khan A, Han L, and Zhou X. Exoplanoplasty Interventions: A Brief Overview of Past, Present, and Future Directions for advanced management of heart failure. Biomed Pharmacother. 2017 88: 162-172.
7. Naveed M, Wenhua L, Gang W, Mohammad IS, Abbas M, Liao X, Yang M, Zhang L, Liu X, Qi X, Chen Y, Jiadi L, Ye L, Zhijie W, CD Ding, Feng Y and Xiaohui Z. A new device for ventricular stress (ASD) repeatedly administering Salvia miltiorrhiza to the epicardium have good curative effects in the management of heart failure. Biomed Pharmacother. 2017 95: 701-710.
8. Zhou XH, LD Li, Wu LM, W Wang, Han L, J Yang, Qiao HX and Zhou XF. Minimally invasive model of myocardial infarction performed by video-badisted thoracoscopic surgery. Methods Find Exp Clin Pharmacol. 2007; 29: 283-90.
Media contact
Company Name: Scientific news
Contact: Barbara E. Hanbad
E-mail: Send an email
Phone: +16467518810
Country: United States
Website: https://www.thescientificnews.com/
[ad_2]
Source link
